Cargando…
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of bevacizumab, the development of GI ulcers has not been reported. We identified 18 patients with ACC who participated in a pha...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480515/ https://www.ncbi.nlm.nih.gov/pubmed/18335169 http://dx.doi.org/10.1007/s10637-008-9125-4 |
_version_ | 1782157954886139904 |
---|---|
author | Tol, J. Cats, A. Mol, L. Koopman, M. Bos, M. M. E. M. van der Hoeven, J. J. M. Antonini, N. F. van Krieken, J. H. J. M. Punt, C. J. A. |
author_facet | Tol, J. Cats, A. Mol, L. Koopman, M. Bos, M. M. E. M. van der Hoeven, J. J. M. Antonini, N. F. van Krieken, J. H. J. M. Punt, C. J. A. |
author_sort | Tol, J. |
collection | PubMed |
description | Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of bevacizumab, the development of GI ulcers has not been reported. We identified 18 patients with ACC who participated in a phase III multicentre trial which included chemotherapy and bevacizumab, who developed a GI ulcer (n = 6), perforation (n = 8) or both (n = 4). The risk of developing a symptomatic GI ulcer or perforation was 1.3% and 1.6%, respectively. Central review of the histology specimens showed ulceration and/or granulation tissue with neovascularisation. The majority (89%) of events developed early during treatment. Given these observations, as well as the relationship between VEGF and mucosal injury healing, we suggest that GI ulcers may occur as a side effect of treatment with bevacizumab and may herald perforation. |
format | Text |
id | pubmed-2480515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-24805152008-07-22 Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation Tol, J. Cats, A. Mol, L. Koopman, M. Bos, M. M. E. M. van der Hoeven, J. J. M. Antonini, N. F. van Krieken, J. H. J. M. Punt, C. J. A. Invest New Drugs Phase III Studies Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of bevacizumab, the development of GI ulcers has not been reported. We identified 18 patients with ACC who participated in a phase III multicentre trial which included chemotherapy and bevacizumab, who developed a GI ulcer (n = 6), perforation (n = 8) or both (n = 4). The risk of developing a symptomatic GI ulcer or perforation was 1.3% and 1.6%, respectively. Central review of the histology specimens showed ulceration and/or granulation tissue with neovascularisation. The majority (89%) of events developed early during treatment. Given these observations, as well as the relationship between VEGF and mucosal injury healing, we suggest that GI ulcers may occur as a side effect of treatment with bevacizumab and may herald perforation. Springer US 2008-03-12 2008 /pmc/articles/PMC2480515/ /pubmed/18335169 http://dx.doi.org/10.1007/s10637-008-9125-4 Text en © The Author(s) 2008 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Phase III Studies Tol, J. Cats, A. Mol, L. Koopman, M. Bos, M. M. E. M. van der Hoeven, J. J. M. Antonini, N. F. van Krieken, J. H. J. M. Punt, C. J. A. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation |
title | Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation |
title_full | Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation |
title_fullStr | Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation |
title_full_unstemmed | Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation |
title_short | Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation |
title_sort | gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation |
topic | Phase III Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480515/ https://www.ncbi.nlm.nih.gov/pubmed/18335169 http://dx.doi.org/10.1007/s10637-008-9125-4 |
work_keys_str_mv | AT tolj gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation AT catsa gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation AT moll gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation AT koopmanm gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation AT bosmmem gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation AT vanderhoevenjjm gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation AT antonininf gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation AT vankriekenjhjm gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation AT puntcja gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation |